Discussion: Evaluating the Efficacy of Treatment, Follow-Up Outcomes, and Recurrence Trends in Pediatric Helicobacter pylori Infections
-
By
-
Toshihiko Kakiuchi
-
September 3, 2026
By
Toshihiko Kakiuchi
September 3, 2026
by Toshihiko Kakiuchi
September 3, 2026
Several FDA decisions across multiple specialties are expected this month.
August 28, 2026
First-generation H1 antihistamines likely increase cognitive impairment, with cognitive effects differing among second-generation antihistamines.
August 31, 2026
Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.
August 28, 2026